Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for 2018 (440 publications)

no pagination
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018 Jan;14(2):123-36.
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner J, Vergote I, Ponte JF, Birrer MJ. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncology. 2018 Jan;14(2):123-36.
Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ. Quality of life during treatment with chemohormonal therapy: Analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. Journal of Clinical Oncology. 2018 Jan;36(11):1088-95.
Mortazavi SM. Comments on “Radiological protection for pregnant women at a large academic medical Cancer Center”. Physica Medica. 2018 Jan;47:144.
Mortazavi SM. Comments on “Sesamol ameliorates radiation induced DNA damage in hematopoietic system of whole body γ-irradiated mice”. Environmental and molecular mutagenesis. 2018 Jan;59(2):170-1.
Mortazavi SM, Mortazavi SA, Paknahad M. Cancers of the brain and CNS: Global patterns and trends in incidence. Journal of Biomedical Physics and Engineering. 2018 Jan;8(1):I-II.
Mortazavi S, Mortazavi S. Comment on ‘Cell phone use and ill health: is there a definite relationship?’. South African Family Practice. 2018 Jan;:1-2.
Moten AS, Lango MN, Goel N, Goldberg AJ. Regional diagnostic rates, treatments, and outcomes among patients with invasive ductal carcinoma. Journal of Surgical Research. 2018 Jan;229:114-21.
Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. Eur Urol. 2018 Jan;73(1):71-8.
Ralff MD, El-Deiry WS. TRAIL pathway targeting therapeutics. Expert Review of Precision Medicine and Drug Development. 2018 Jan;3(3):197-204.
Regine WF, Winter K, Abrams RA, Safran H, Kessel IL, Chen Y, Fugazzi JA, Donnelly ED, DiPetrillo TA, Narayan S, Plastaras JP, Gaur R, Delouya G, Suh JH, Meyer JE, Haddock MG, Didolkar MS, Padula GD, Johnson D, Hoffman JP, Crane CH. Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Advances in Radiation Oncology. 2018 Jan;3(2):154-62.
Reyngold M, Niland J, ter Veer A, Bekaii-Saab T, Lai L, Meyer JE, Nurkin SJ, Schrag D, Skibber JM, Benson AB, Weiser MR, Crane CH, Goodman KA. Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. Advances in Radiation Oncology. 2018 Jan;3(1):34-41.   PMCID: PMC5856979
Ristau BT, Chen DY, Ellis J, Malhotra A, DeMora L, Parsons RB, Milestone B, Brody M, Viterbo R, Greenberg R, Smaldone M, Uzzo R, Anaokar J, Kutikov A. Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy. Journal of Urology. 2018 Jan;199(4):969-75.
Ristau BT, Manola J, Haas NB, Heng DY, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. Journal of Urology. 2018 Jan;199(1):53-9.
Ristau BT, Manola J, Haas NB, Heng DY, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG. Retroperitoneal Lymphadenectomy in High-Risk Non-Metastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol. 2018 Jan;199(1):53-9.   PMCID: PMC5800986
Ristau BT, Manola J, Haas NB, Heng DY, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. Journal of Urology. 2018 Jan;199(1):53-9.
Ristau BT, Smaldone MC. Editorial Comment. Journal of Urology. 2018 Jan;199(4):914.
Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. International Journal of Radiation Oncology Biology Physics. 2018 Jan;101(4):883-8.
Saxon B, Bass SB, Wright T, Panick J. Ebola and the rhetoric of US newspapers: assessing quality risk communication in public health emergencies. Journal of Risk Research. 2018 Jan;:1-14.
Seliga A, Lee MH, Fernandes NC, Zuluaga-Ramirez V, Didukh M, Persidsky Y, Potula R, Gallucci S, Sriram U. Kallikrein-Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation. Frontiers in immunology. 2018 Jan;9:156.   PMCID: PMC5801412
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications for the year 2018


Last updated on Tuesday, July 03, 2018